Is Eikon Therapeutics, Inc. Common Stock (EIKN) Stock Halal?
Compliance Status
Not Halal
Screened on Nov 12, 2026 · AAOIFI Standard 21
Non-Compliant
Is Eikon Therapeutics, Inc. Common Stock (EIKN) halal? Not Halal. Based on AAOIFI screening, Eikon Therapeutics, Inc. Common Stock passes the business activity screen but fails financial ratio screens with a compliance score of 0/100 (Grade: F).
Quote this verdict
HalalScreener rates Eikon Therapeutics, Inc. Common Stock (EIKN) Not Halal, 0/100, grade F under AAOIFI Standard 21, screened Nov 12, 2026. Source: https://halalscreener.app/en/stock/EIKN
Business activity
What the company sells is permissible.
Company debt
Over the limitHow much the company borrows, compared to its total value. AAOIFI allows up to 30%.
The verdict above is final and free.
Pro members can verify every number behind it: interest-bearing deposits, prohibited income breakdown, and the full AAOIFI math.
Screened according to AAOIFI Standard 21
What this means for you
Most scholars advise not holding EIKN
It does not pass AAOIFI Shariah screening.
See halal alternatives from the same sector further down this page
Share this verdict
A receipt-style image with the math on it, so whoever you send it to can check it.

EIKN
Eikon Therapeutics, Inc. Common Stock
$6.67
Market Cap: 361.1M
Get an email if EIKN's halal status changes
We re-screen Eikon Therapeutics, Inc. Common Stock daily. If the verdict moves, you hear about it the same day.
Free. One click sets it up, and you can unsubscribe any time.
About Eikon Therapeutics, Inc. Common Stock
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.
Sector: Healthcare · Industry: Biotechnology
Why this does not pass
- Interest-bearing debt is 69.1% of market cap, over the 30% AAOIFI limit.
- Interest-bearing deposits are over the 30% limit.
Screened under AAOIFI Standard 21. The exact figure behind this is part of Pro; the failing check and its limit are always free.
Shariah Compliance Status
Compliance History
Not Halalnow
since Aug 2026
Under Review
until the change above
Tracked since Aug 2026. Updates automatically on each re-screen.
Halal Alternatives in Healthcare
This stock is not Shariah-compliant. Here are halal alternatives from the same sector, ranked by compliance score:
More Healthcare Stocks
Know the day EIKN's verdict changes
A free account keeps watch on 3 stocks and emails you when a verdict moves. You also get 3 questions for the AI Scholar. No card needed.
Frequently Asked Questions
Is Eikon Therapeutics, Inc. Common Stock (EIKN) halal to invest in?
Why did Eikon Therapeutics, Inc. Common Stock get a F compliance rating?
What could change Eikon Therapeutics, Inc. Common Stock's Shariah verdict?
How often is Eikon Therapeutics, Inc. Common Stock re-screened for Shariah compliance?
Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.
Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.
